Prurigo Nodularis (PN) Market is Projected to Boost at a Moderate Growth Rate by 2032 – DelveInsight | Menlo Therapeutics, Galderma, Kiniksa Pharma, Sanofi, Maruho, Trevi Therapeutics, Kiniksa Pharma

Prurigo Nodularis (PN) Market is Projected to Boost at a Moderate Growth Rate by 2032 - DelveInsight | Menlo Therapeutics, Galderma, Kiniksa Pharma, Sanofi, Maruho, Trevi Therapeutics, Kiniksa Pharma

“Delveinsight Business Research LLP”
The Prurigo Nodularis market size is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.

DelveInsight’s “Prurigo Nodularis (PN) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Prurigo Nodularis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Prurigo Nodularis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Prurigo Nodularis Market

Prurigo Nodularis: An Overview

Prurigo nodularis (PN), one of the various subtypes of prurigo, is a chronic, bothersome-to-debilitating disease of the skin, usually seen as multiple, intensely pruritic, and excoriated nodules erupting on the surfaces of the extremities with intense itching or rubbing.

Prurigo Nodularis are cutaneous lesions often produced by repetitive scratching; hence the nickname “picker’s nodules”, which may occur as a sequel to chronic pruritus or neurotic excoriations. After establishing a perpetual itch-scratch cycle, lichenification of the skin may ensue, resulting in chronic dermatitis termed lichen simplex chronicus. Several lesions in different stages and sizes may co-exist in patients with chronic pruritus, which is induced by chronic scratching.

Prurigo Nodularis Market Key Facts

  • The total prevalent population of Prurigo Nodularis in the seven major markets was found to be 689,760 in 2017.

  • Japan accounted for the second-highest prevalent population of Prurigo Nodularis among the 7MM countries, with over 110,681 cases in 2017, which will increase by the end of 2032.

  • The total prevalent population of Prurigo Nodularis in the seven major markets was found to be 693,170 cases in 2018.

  • Among the European countries, Germany had the highest prevalent population of Prurigo Nodularis, with 103,004 cases, followed by France, with 57,996 cases in 2017. Besides, Spain had the lowest prevalent population, with 44,273 cases in 2017. 

Prurigo Nodularis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Prurigo Nodularis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Prurigo Nodularis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Prurigo Nodularis Epidemiology

As per DelveInsight, the Prurigo Nodularis market size is expected to increase during the forecast period owing to the rise in the number of the prevalent population of Prurigo Nodularis in the 7MM and the launch of the emerging therapies.

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Prurigo Nodularis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched during the study period. The analysis covers Prurigo Nodularis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Prurigo Nodularis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Prurigo Nodularis Market Will Evolve by 2032 @

Prurigo Nodularis Therapeutics Analysis

There are approx. 5+ key companies which are developing therapies for Prurigo Nodularis. Currently, Chugai/Galderma has its Prurigo Nodularis drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Prurigo Nodularis Therapeutics Market include:

• Menlo Therapeutics

• Galderma R&D

• Kiniksa Pharmaceuticals

• Sanofi

• Maruho 

• Trevi Therapeutics

• Kiniksa Pharmaceuticals

And many others.

Prurigo Nodularis Emerging Drugs Covered in the report include:

• Nemolizumab (Chugai/Galderma)

• Nalbuphine ER (Trevi Therapeutics)

• Vixarelimab (Kiniksa Pharmaceuticals)

• Serlopitant

• Nalbuphine ER

• KPL-716

• Dupilumab

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Prurigo Nodularis Competitive Intelligence Analysis

4. Prurigo Nodularis Market Overview at a Glance

5. Prurigo Nodularis Disease Background and Overview

6. Prurigo Nodularis Patient Journey

7. Prurigo Nodularis Epidemiology and Patient Population (In US, EU5, and Japan)

8. Prurigo Nodularis Treatment Algorithm, Current Treatment, and Medical Practices

9. Prurigo Nodularis Unmet Needs

10. Key Endpoints of Prurigo Nodularis Treatment

11. Prurigo Nodularis Marketed Products

12. Prurigo Nodularis Emerging Drugs and Latest Therapeutic Advances

13. Prurigo Nodularis Seven Major Market Analysis

14. Attribute Analysis

15. Prurigo Nodularis Market Outlook (In US, EU5, and Japan)

16. Prurigo Nodularis Access and Reimbursement Overview

17. KOL Views on the Prurigo Nodularis Market

18. Prurigo Nodularis Market Drivers

19. Prurigo Nodularis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Andersen-Tawil Syndrome Market

“Andersen-Tawil Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Andersen-Tawil Syndrome Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States